Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07114874 · ClinicalTrials.gov registry record · Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by Neurocrine Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT07114874 is a Phase 3 study of Schizophrenia that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 800 participants, above the 216-participant average among 315 other Schizophrenia trials with a reported enrollment target (270% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT07114874, a Phase 3 study of Schizophrenia, is actively recruiting participants, sponsored by Neurocrine Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
Conditions Studied
Interventions
- DRUG NBI-1117568
Study Locations (20)
California
- Neurocrine Clinical Site - Culver City
- Neurocrine Clinical Site - Garden Grove
- Neurocrine Clinical Site - Pico Rivera
- Neurocrine Clinical Site - Riverside
- Neurocrine Clinical Site - San Diego
- Neurocrine Clinical Site - Sherman
- Neurocrine Clinical Site - Torrance
Georgia
- Neurocrine Clinical Site - Atlanta
- Neurocrine Clinical Site - Atlanta
- Neurocrine Clinical Site - Decatur
- Neurocrine Clinical Sites - Peachtree Corners
Florida
- Neurocrine Clinical Site - Hollywood
- Neurocrine Clinical Site - Miami Lakes
Arkansas
- Neurocrine Clinical Site - Little Rock
Illinois
- Neurocrine Clinical Site - Chicago
Maryland
- Neurocrine Clinical Site - Gaithersburg
Massachusetts
- Neurocrine Clinical Site - Watertown
Missouri
- Neurocrine Clinical Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2031-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07114874
The ClinicalTrials.gov registry entry for NCT07114874 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 216-participant average among 315 other Schizophrenia trials with a reported enrollment target (270% higher). The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which NBI-1117568 is the first listed.
NCT07114874 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT07114874 about?
NCT07114874 is a clinical study titled "NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia". This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
What is the current status of trial NCT07114874?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-07-11. Estimated completion is 2031-12.
What conditions does trial NCT07114874 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07114874?
The interventions under investigation include: NBI-1117568 (DRUG).
Who is sponsoring clinical trial NCT07114874?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07114874 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
-
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.